

#019 Augmentin, India's Top Selling Drug
On today’s episode, financial journalist Govindraj Ethiraj talks to Sheetal Sapale, vice president at integrated healthcare technology platform Pharmarack as well as Tushar Sachade, Partner at PricewaterhouseCoopers & Company. SHOW NOTES [00:50] Did you know which is India’s top selling drug and more importantly for…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Core Report
See all episodes →
#1021 Are Investors Ignoring India’s Best Value Stocks? Sanjeev Prasad | Govindraj Ethiraj | The Core Report

#1014 Why Foreign Investors Are Selling Indian Stocks | Ajit Dayal | Govindraj Ethiraj | The Core Report

#1033 Indian Stock Market Rebounds. Should Your Portfolio Change? | Govindraj Ethiraj | The Core Report Weekend Edition
Similar episodes from other shows
More like The Core Report →
The Biggest Indian Pharma Deal of the Decade

How can India’s pharma companies survive under Trump’s uncertainty?

India’s CDMO surge: The business behind the Drugs

Overhauling drugs law, Maha's new bike taxi rules, and Tata Sons' chairman
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.